Skip to content
  • +44 808 189 5057 (toll free)
  • clientserviceseurope@guardanthealth.com

Conquering cancer
with data

Through the power of blood tests, we can uncover clues that allow doctors to discover cancer early and find the best way to treat it.

Explore our approach

Experience the next era
of liquid biopsy, today.

Adjuvant

Adjuvant

Guardant Reveal™ is the first liquid-only Minimal Residual Disease (MRD) detection test with high landmark sensitivity at 4 weeks post-surgery to help with therapy decisions in early-stage patients with colorectal cancer, breast and lung cancer.1,2

Discover Guardant Reveal™

Recurrence

Recurrence

Guardant Reveal™ is the first validated liquid-only Minimal Residual Disease (MRD) detection test with up to 91% sensitivity to help detect recurrence in colorectal, breast and lung cancer surveillance.1,2

Discover Guardant Reveal™

Advanced

Advanced

Guardant360® CDx is a guideline-recommended* genomic profiling blood test with results in 5 days to help optimize treatment selection quickly.3,4

Discover Guardant360® CDx

Progression

Progression

Guardant360® Liquid is a guideline-complete* genomic profiling test powered by Guardant Infinity platform that comes with novel test features with results in 7 days for a complete view of cancer.5

Discover Guardant360® Liquid

A portfolio of revolutionary liquid precision oncology tests, all with the convenience of a single testing company.3,5

Product Selector

Discover all liquid testing options.

Guardant360® CDx

Guideline-recommended* testing of 74 genes at diagnosis & progression.

5 days†

To Guardant 360® CDx
Information Provided
Any Advanced Solid Tumour
Liquid Test
Turnaround Time

Guardant360® Liquid

Guideline-complete** testing of 740+ genes at diagnosis & progression.

7 days†

To Guardant 360® Liquid

Guardant Reveal™

Information Provided

Residual disease and recurrence monitoring

For Selected Solid Tumours

Stage II or III colorectal, breast, and lung cancer

Liquid Test
Turnaround Time

7 days†

Explore product

Guardant Shield™

Coming soon to international markets!

Find out more

Important Note: Guardant Reveal™ and Guardant360® Liquid were developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the US FDA. Guardant Hereditary Cancer was developed as an LDT and is not cleared or approved by the US FDA.

Continuum Of Care

Cancer Stages Line
Surgery Recurrence Progression

Patient timeline

Early-Stage Cancer

Residual disease detection
and recurrence monitoring

Guardant Reveal

Advanced-Stage Cancer

Treatment selection and monitoring

Guardant 360 CDx
Guardant 360

*Guideline-recommended in oncology, including coverage of all biomarkers specified in the NCCN guidelines for advanced solid tumors.
**Guideline-complete for genomic biomarkers across advanced solid tumors, including emerging biomarkers that may impact treatment planning in the future.
The first and only commercially available liquid biopsy to deliver genomic and epigenomic insights from a single input. †Median turnaround time from sample receipt to results.

References: 1. Guardant Health data on file. October 19, 2023. Guardant Health, Inc. Redwood City, CA. (Reveal MRD positioning.), 2. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586-5594. doi:10.1158/1078-0432.CCR-21-0410, 3. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. February 2023., 4. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test. August 7, 2020. Accessed October 31, 2022. https://www.fda.gov/news-events/pressannouncements/ fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test,
5. Guardant360R Assay Specifications. Guardant Health, Inc. Redwood City, CA. October 14, 2024., 6. Guardant Health data on file. September 27, 2024. Guardant Health, Inc. Redwood City, CA.